296 results on '"Simons, Brian W."'
Search Results
2. [18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response
3. Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
4. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model
5. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer
6. The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates
7. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
8. Role of Adenosine Deaminase in Prostate Cancer Progression
9. Magnetic Resonance Imaging and Molecular Characterization of a Hormone-Mediated Murine Model of Prostate Enlargement and Bladder Outlet Obstruction
10. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer
11. Supplementary Fig. S4 from Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites
12. Data from Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites
13. Data from Stromal CAVIN1 Controls Prostate Cancer Microenvironment and Metastasis by Modulating Lipid Distribution and Inflammatory Signaling
14. Supplementary Figures 1-5 from Stromal CAVIN1 Controls Prostate Cancer Microenvironment and Metastasis by Modulating Lipid Distribution and Inflammatory Signaling
15. Figure S1 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
16. Supplementary Data from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
17. Supplementary Figure Legends from Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites
18. Supplementary Methods from Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites
19. Supplementary Data TS5 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
20. Supplementary Data from Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression
21. Supplemental Figures from TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis
22. Supplementary Tables S6 and S7 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
23. Data from TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis
24. Data from Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression
25. Supplementary Materials and Methods from Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression
26. Supplementary Materials and Methods from TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis
27. Supplementary Figure S1 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
28. Supplementary Figure S5. SPARCL-1 coated beads do not reinforce cellular traction. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
29. Supplementary Figure S7. Responses to SPARCL1-coated beads are concentration dependent. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
30. Data from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
31. Supplementary Figure S3. The tumor microenvironment in Sparcl1-/- models. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
32. Supplementary Figure S6. SPARCL1 engages cell-ECM interactions. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
33. Supplementary Figure 6 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
34. Supplementary Figure S2. AR directly represses SPARCL1 expression in prostate cancer. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
35. Supplementary Figure 2 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
36. Supplementary Figure 7 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
37. Supplementary Figure Legend from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
38. Supplementary Figure 5 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
39. Supplementary Figure S4. SPARCL1 inhibits cytoskeletal remodeling. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
40. Supplementary Table 2 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
41. Supplementary Figure S1. Androgen suppresses SPARCL1 expression. from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
42. Data from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
43. Supplementary Figure 3 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
44. Supplementary Materials and Methods and Supplementary Figure Legends from Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression
45. Supplementary Figure 4 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
46. Supplementary Figure 1 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
47. Supplementary Table 1 from Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
48. Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy
49. Spatial analysis of nanoparticle distribution in human breast xenografts reveals nanoparticles targeted to cancer cells localized with tumor-associated stromal cells.
50. Cover Image: Volume 83 Issue 3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.